Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

被引:51
作者
Corbett, TH
LoRusso, P
Demchick, L
Simpson, C
Pugh, S
White, K
Kushner, J
Polin, L
Meyer, J
Czarnecki, J
Heilbrun, L
Horwitz, JP
Gross, JL
Behrens, CH
Harrison, BA
McRipley, RJ
Trainor, G
机构
[1] Wayne State Univ, Barbara Karmanos Canc Inst, Sch Med, Detroit, MI 48202 USA
[2] DuPont Pharmaceut Co, Wilmington, DE USA
关键词
preclinical; antitumor; XK469; analog;
D O I
10.1023/A:1006174622061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of quinoxaline analogs of the herbicide Assure(R) was found to have selective cytotoxicity for solid tumors of mice in a disk-diffusion-soft-agar-colony-formation-assay compared to L1210 leukemia. Four agents without selective cytotoxicity and 14 agents with selective cytotoxicity were evaluated in vivo for activity against a solid tumor. The four agents without selective cytotoxicity in the disk-assay were inactive in vivo (T/C > 42%). Thirteen of the fourteen agents with selectivity in the disk-assay were active in vivo (T/C < 42%). Five of the agents had curative activity. These five agents had a halogen (F, Cl, Br) in the 7-position (whereas Assure(R) had a Cl in the 6 position). All agents with curative activity were either a carboxylic acid, or a derivative thereof, whereas Assure(R) is the ethyl ester of the carboxylic acid. All other structural features were identical between Assure(R) and the curative agents. Assure(R) had no selective cytotoxicity for solid tumors in the disk-assay, and was devoid of antitumor activity. The analog XK469 is in clinical development.
引用
收藏
页码:129 / 139
页数:11
相关论文
共 33 条
[1]   CELLULAR PHARMACOLOGY OF CHLOROQUINOXALINE SULFONAMIDE AND A RELATED COMPOUND IN MURINE B-16 MELANOMA-CELLS [J].
BRANDA, RF ;
MCCORMACK, JJ ;
PERLMUTTER, CA .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (23) :4557-4564
[2]   IMMUNOSUPPRESSIVE PROPERTIES OF CHLOROQUINOXALINE SULFONAMIDE [J].
BRANDA, RF ;
MOORE, AL ;
MCCORMACK, JJ .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (20) :3521-3526
[3]  
CONLEY BA, 1995, CANCER CHEMOTH PHARM, V37, P139
[4]   TUMOR-MODELS AND THE DISCOVERY AND SECONDARY EVALUATION OF SOLID TUMOR ACTIVE AGENTS [J].
CORBETT, T ;
VALERIOTE, F ;
LORUSSO, P ;
POLIN, L ;
PANCHAPOR, C ;
PUGH, S ;
WHITE, K ;
KNIGHT, J ;
DEMCHIK, L ;
JONES, J ;
JONES, L ;
LOWICHIK, N ;
BIERNAT, L ;
FOSTER, B ;
WOZNIAK, A ;
LISOW, L ;
VALDIVIESO, M ;
BAKER, L ;
LEOPOLD, W ;
SEBOLT, J ;
BISSERY, MC ;
MATTES, K ;
DZUBOW, J ;
RAKE, J ;
PERNI, R ;
WENTLAND, M ;
COUGHLIN, S ;
SHAW, JM ;
LIVERSIDGE, G ;
LIVERSIDGE, E ;
BRUNO, J ;
SARPOTDAR, P ;
MOORE, R ;
PATTERSON, G .
INTERNATIONAL JOURNAL OF PHARMACOGNOSY, 1995, 33 :102-122
[5]  
CORBETT T., 1994, Expert Opinion on Investigational Drugs, V3, P1281
[6]  
Corbett T H, 1996, J Exp Ther Oncol, V1, P95
[7]  
CORBETT TH, 1977, CANCER, V40, P2660, DOI 10.1002/1097-0142(197711)40:5+<2660::AID-CNCR2820400940>3.0.CO
[8]  
2-M
[9]  
CORBETT TH, 1984, CANCER RES, V44, P717
[10]  
CORBETT TH, 1984, P AM ASSOC CANC RES, V25, P325